Introduction
Interleukin-17 (IL-17) is implicated in the pathogenesis of multiple sclerosis (MS). In active brain lesions, it is expressed by T helper 17 (Th17) cells and by astrocytes and oligodendrocytes in the central nervous system (CNS) where it synergizes with other pro-inflammatory cytokines and mediators of tissue damage (Kang et al. , 2010 , Tzartos et al. , 2008 , Waisman et al. , 2015 . IL-17A and IL-17F form homo-or heterodimers that bind to the IL-17 receptor complex (IL-17RA and IL-17RC) (Waisman, Hauptmann, 2015) . IL-17 disrupts barrier integrity of both human brain-derived primary microvascular endothelial cells (Kebir et al. , 2007 , Rahman et al. , 2018 ) and a murine brain endothelial cell line, bEnd.3 (Huppert et al. , 2010) . IL-17 is important for the development of experimental autoimmune encephalomyelitis (EAE) (Langrish et al. , 2005 , McGinley et al. , 2018 . In IL-17A -/-mice, the blood-brain barrier (BBB) is less disrupted in induced EAE and disease scores are lower (Huppert, Closhen, 2010) . Presurgical treatment with anti-IL17A reduced BBB disruption in aged, wild-type C57BL/6J mice that suffered from perioperative neurocognitive disorders (Ni et al. , 2018) .
Here, we applied a translational approach to study the effects of IL-17 on the development of experimental MS and BBB integrity. Blockade of IL-17A, but not IL-17F, attenuated disease activity in EAE. IL-17A was elevated in the CSF of RRMS patients, which was correlated with a surrogate measure of BBB integrity in 2 independent cohorts. Finally, a combination of IL-17A and IL-6 stimulation decreased invitro endothelial cell monolayer integrity.
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Materials and Methods
Antibody Characterization
Anti-mouse IL-17A monoclonal antibody (Mab) (PRO97156) was produced inhouse by transient co-expression of immunoglobulin sequences isolated from a single clonal hamster/mouse chimeric hybridoma along with mouse IgG2a  DNA sequences in
Chinese hamster ovary cells. Clonal hamster/mouse hybridoma lines were derived from hamsters immunized with mouse IL-17AA immunogen. Anti-mouse IL-17, anti-IL-17AF
(clone 16H4.4F3, Novimmune, Switzerland) and anti-IL17F (clone 28E12, Novimmune, Switzerland) were confirmed to block recombinant IL-17A and F-induced mIL-6 by mouse embryonic fibroblasts (MEFs) derived from Il-17Rc-deficient mouse reconstituted with FLAG-tagged IL-17RC as previously described (Hu et al. , 2010) .
MEFs were plated at 12.5  10 3 cells per well in a 96-well microtiter cell culture plate (Corning, Tewksbury, MA) in DMEM supplemented with 10% fetal bovine serum (Hyclone, Logan, UT), 2 mM GlutaMAX I (Invitrogen, Carlsbad, CA), 1 mM sodium pyruvate (Invitrogen), 0.1 mM non-essential amino acids (Hyclone), 55 M 2-mercaptoethanol (Invitrogen), and 100 U/mL penicillin and 100 g/mL streptomycin mixture (Invitrogen). After overnight incubation in a humidified incubator at 37C with 5% CO 2 , cells were stimulated with the same medium containing 100 nM anti-IL-17 or an isotype matched control antibody as well as recombinant mouse (rm) IL-17AA, FF or AF protein (R&D Systems, Minneapolis, MN) at 1, 50 or 0.2 ng/mL, respectively. Each condition was carried out in triplicate. Supernatants were collected 2 days A C C E P T E D M A N U S C R I P T post-stimulation and the level of mIL-6 was measured using a mouse IL-6 DuoSet ELISA Kit (R&D Systems).
EAE development and anti-IL-17 antibodies treatment
The Institutional Animal Care and Use Committee (IACUC) at Genentech approved the protocols for animal experiments. All of the animal experiments were carried out in accordance with all applicable laws, regulations, guidelines, and policies governing the use of laboratory animals in research.
EAE was induced in 9-week-old female C57BL/6 mice. Human IL-17A and IL-17F levels were quantified using the Singulex platform (Singulex, Alameda, CA) as previously described (Schofield et al. , 2016) . Proinflammatory cytokines and chemokines were quantified using a combination of electrochemiluminescence and multi-array technology (McKay et al. , 2017) . ELISAbased assays were performed to measure the levels of neurofilament light chain (NFL) (UmanDiagnostics, Umea, Sweden) and glial fibrillary acidic protein (GFAP) (BioVendor Inc., Asheville, NC). Albumin in "Cohort 1" was measured using Human Serum Albumin ELISA kit (Sigma-Aldrich, St. Louis, MO). In "Cohort 2", albumin was measured in the UCSF clinical laboratory using bromocresol purple (BCP) reagent and at Quest Diagnostics (various locations, USA) using Fixed Rate Time Nephelometry; the albumin quotient (Qalb) was calculated as the ratio of CSF/serum albumin. Concentration
of analytes that fell below the lower limit of quantification (LLOQ) were imputed as half of the LLOQ of the assay. Quantification of all proteins was performed prior to freezethaw cycles.
Human brain endothelial cell culture, cytokine treatments and RNA extraction
Human cerebral microvascular endothelial cells (hCMEC/D3) (Weksler et al. , 2013 , Weksler et al. , 2005 at passages 26-35 were cultured on rat-tail collagen type Icoated tissue culture plates (for gene expression studies) or Transwell® inserts (for assessments of cell monolayer integrity) containing EBM-2 basal medium (Lonza, Walkersville, MD) supplemented with the EGM-2 SingleQuot reagents obtained from the manufacturer. Cells were maintained at 37°C and 5% CO2 until confluence.
Immortalized hCMEC/D3 cell line was kindly provided by Ashley Hayes, F. HoffmannLa Roche Ltd., Basel, Switzerland. Rat-tail collagen type I was obtained from Gibco,
Madison, WI.
Recombinant human (rh) IL17A, rhTNF-, rhIL6 and rhIL6R were purchased from R&D Systems. The experiments were run in 2-fold serial dilutions for each cytokine. Final concentrations used in this study: 50 ng/ml IL-17A  1 ng/ml TNF- or 25 ng/ml IL-6 + 50 ng/ml IL-6R. For gene expression analyses, total RNA was extracted using RNeasy Mini Kit (QIAGEN) after 2 days of treatment with the cytokines.
Quantitative Real-time PCR (qPCR)
Complementary DNA (cDNA) was synthesized using iScript cDNA Synthesis Kit (Biorad, Hercules, CA) using 100ng RNA per sample. Following pre-amplification steps, Hs00901465_m1, Pecam1: Hs01065282_m1, Jam1: Hs00170991_m1, Cldn3:
Hs01003267_m1, Gusb: Hs00939627_m1.
Assessment of cell monolayer integrity by trans-endothelial electrical resistance (TEER) measurement and lucifer yellow (LY) fluorescent marker
hCMEC/D3 cells were seeded at 6.0x10 4 cells/cm 2 on the apical side of an 0.4 μm polyester membrane (Corning, NY) pre-coated with rat-tail collagen type I. The cells were grown on the 6.5 mm-diameter, 24-well tissue culture Transwell® inserts for 4 days to near confluency, prior to an exchange of medium and 1 to 3 days of treatment with the cytokines. The monolayer integrity was assessed by (TEER) measurement (Srinivasan et al. , 2015) . Cells cultured on the inserts were allowed to equilibrate to room temperature for 20 minutes. A small aliquot of cells from each treatment group was set aside and stained with trypan blue (Life Technologies, Carlsbad, CA) to confirm >95% viability.
An EVOM™ Epithelial Voltohmmeter and chopstick electrodes (World Precision
Instruments, UK) were used for the measurement of the electrical resistance of 
Statistical analyses
All statistical comparisons were made using either a Wilcoxon rank sum test on each pair (unadjusted for multiple hypothesis testing) or ANOVA with Dunnett's test.
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For all tests, p<0.05 was considered significant and 0.05≤ p≤0.1 was considered a trend.
Correlation analyses were done using Spearman's method.
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Results
Blockade of IL-17A, but not IL-17F, attenuated the development of EAE
Cell-based assays showed that the anti-IL-17A Mab (PRO97156) and anti-IL17-AF (16H4.4F3) blocked both IL-17AA and IL-17AF (Fig. 1A) . (clone 16H4.4F3 + 28E12). Anti-IL-17F alone did not lower the clinical scores (Fig. 1B) .
Elevated IL-17A in the CSF from RRMS patients correlated with Qalb in Cohort 1
Levels of IL-17A and F in the CSF from RRMS patients and healthy donors (HD)
were assessed with an immunoassay that resolved IL-17A and IL-17F isoforms (Schofield, Fischer, 2016) . IL-17A was detectable in the CSF in 38/50 (76%) RRMS patients and in 7/20 (35%) HD. It was elevated in the CSF from RRMS patients (n=50)
vs. HD (n=20) (Fig. 2A) . IL-17F was also detectable in the CSF from 12/50 (24%)
RRMS patients and 1/20 (5%) HD; however, the levels in RRMS vs. HD were not significantly different ( Fig. 2A) .
Since IL-17A has previously been reported to play important roles in CNS inflammatory responses (Waisman, Hauptmann, 2015) , we measured inflammatory
proteins, chemokines and cytokines in the CSF as well as the CSF levels of markers of neuronal (NFL) and glial cell damage (GFAP) (Constantinescu et al. , 2016) . Eotaxin, CXCL10, TARC, MCP4, and NFL were significantly higher in the RRMS CSF vs. HD (Fig. 2B) . Elevated levels of CRP, SAA, ICAM1, VCAM1 and cytokines such as IFN-, IL-8, IL-12, IL-1, IL-2, IL-6 and TNF- were observed in the CSF from some RRMS patients; however, the differences vs. HD were not statistically significant (p>0.05, Wilcoxon rank sum test). GFAP was not elevated in RRMS CSF vs. HD (p=0.8,
Wilcoxon rank sum test).
We determined whether the levels of IL-17A in the CSF were associated with the Qalb, a measure of patients' impairment of BBB integrity (Anckarsater et al. , 2005 , Reiber, 2001 , Tibbling et al. , 1977 , age, gender, disease duration or Expanded Disability Status Scale (EDSS). We found a positive correlation between IL-17A and Qalb (Spearman's rho = 0.34; p=0.016) (Fig. 3A) . Although NFL, Eotaxin, CXCL10, TARC and MCP4 were significantly elevated in the RRMS CSF, these did not correlate with Qalb ( Fig. 3C) , suggesting a direct contribution of IL-17A to BBB damage. Male patients displayed higher levels of CSF IL-17A than female patients ( Supplementary Fig. 1A, Fig. 2A , p=0.9).
p=0.001). No other correlation was observed between CSF IL-17A and other patients' demographics and clinical parameters, including MS medication status (Supplementary
Correlation of IL-17A in CSF with Qalb in a second, independent cohort of RRMS patients with < 1 year of disease
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We assessed a second RRMS cohort (n=69) with MRI data available (Table 1) .
This cohort contained an earlier stage of RRMS with lower EDSS scores than the first cohort ( Table 1 ). The levels of CSF IL-17A and pro-inflammatory chemokines (MCP1, MIP-1b and TARC) were lower than the first cohort, although CXCL10 levels were similar ( Supplementary Fig. 3 ).
Despite these differences, we found that, similar to the first cohort, CSF IL-17A levels also correlated with Qalb in this second cohort (Fig. 3B) . No significant relationships between CSF IL-17A levels and the presence of oligoclonal bands (OCB), cervical and thoracic T2 lesions in the spine, and Gadolinium (Gd+) T1 lesions in the spine and brain were observed (Supplementary Table 1 ). Further, no correlation was observed between the number of T1 Gd+ lesions in spine and brain with CSF IL-17A levels (Spearman's rho was 0.1 (p=0.5) and -0.03 (p=0.8), respectively) as reported in Supplementary Table 2 .
Unlike the first cohort, no gender difference in CSF IL-17A levels were observed in the second cohort ( Supplementary Fig. 1B , p=0.4), but a weak, inverse correlation was observed between CSF IL-17A and age (Supplementary Supplementary Fig. 2B , p=0.7), MRI findings, disease duration and EDSS (Supplementary Table 2 ).
Treatment of endothelial cells with rhIL-17A in the presence of IL-6+IL-6R reduced tight junction gene expression and impaired endothelial cell monolayer integrity
A C C E P T E D M A N U S C R I P T
We treated the hCMEC/D3 brain endothelial cell line with rhIL-17A for 2 days, in the presence of TNF- or IL-6 + IL-6R that had been implicated in MS pathogenesis and BBB breakdown (Jadidi-Niaragh and Mirshafiey, 2011 , Luchtman et al. , 2014 , Minagar and Alexander, 2003 , Montgomery and Bowers, 2012 , Quintana et al. , 2009 , to assess the response of genes encoding TJ-associated proteins (Ocln, Tjp1, Jam1, Cldn3 and Cldn5), an adherens junction protein and adhesion molecule, Cdh5 and Pecam1, respectively, that are known to be expressed in the cell line (Weksler, Subileau, 2005) .
The expression of 4 genes (Ocln, Tjp1, Cdh5 and Pecam1) was significantly reduced after IL-17A + IL-6 + IL-6R treatment, compared to PBS control. Jam1 trended down after IL-17A + IL-6 + IL-6R treatment. Significant Pecam1 decrease and a trend for
Cdh5 and Tjp1 decrease were observed upon treatment of the cells with IL-17A alone.
The most pronounced reduction in the expression of the 5 genes occurred with a combination of IL-17A and IL-6 + IL-6R. Expression of Pecam1 and Cdh5 was also significantly decreased with TNF- alone, and Pecam1 was further reduced with a combination of IL-17A and TNF- (Fig. 4A ). Cldn3 and Cldn5 expression levels were not affected by any of the treatments (data not shown).
We then assessed monolayer integrity after treatment with IL-17A + IL-6 + IL-6R using TEER and solute transport assays. IL17A alone did not significantly decrease the TEER (Fig. 4B ) or increase permeability of the cell monolayer to LY (Fig. 4C) . In contrast, IL-17A + IL-6 + IL-6R lowered the TEER compared to PBS control as soon as 1 day after treatment (Fig. 4B) . The monolayer in the IL-17A + IL-6 + IL-6R treated group also displayed higher permeability to LY versus PBS control as assessed after 3 days of treatment (Fig. 4C) .
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Discussion
We found that IL-17A, but not IL-17F, contributed to EAE pathogenesis. This observation is consistent with previous reports that CNS-infiltrating Th17 cells in EAE predominantly expressed IL-17A, and the expression of IL-17F was associated with nonpathogenic Th17 cells (Wanke et al. , 2018) .
Analyses of IL-17A levels in the CSF from two independent cohorts of RRMS patients showed a consistent result that CSF IL-17A positively correlated with Qalb, a measure of BBB damage in RRMS. This is the first report that CSF IL-17A levels were positively correlated with Qalb in RRMS, in both the early (Cohort 2) and late (Cohort 1) stages of the disease. The positive correlation in the early RRMS cohort suggests that IL-17A could play a role in early BBB disruption during MS pathophysiology. A direct contribution of IL-17A to BBB damage was further supported by the observation that other pro-inflammatory chemokines that were significantly elevated in the Cohort 1 RRMS CSF, such as Eotaxin, CXCL10, TARC and MCP4, did not correlate with the Qalb.
In the RRMS Cohort 2, we found a lack of correlation between CSF IL-17A levels and the presence OCB, as well as with the numbers of T1 Gd+ and T2 lesions. A previous study reported that the number and the volume of Gd-enhancing lesions are highly correlated (Rovaris et al. , 1999) . Although the presence of Gd+ lesions in the CNS indicates active lesions, it may underrepresent the overall extent of BBB disruption (Waubant, 2006) . The lack of correlation between IL-17A levels and Gd positivity suggests that IL-17A elevation is not solely explained by the presence of active lesions.
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Although relapse information was not collected for the cohorts studied, and the absence of correlation with EDSS and MRI Gd + lesions suggests that there is also no correlation with relapse activity. To further address whether medication treatment may have confounded these results (for example, treatment escalation may have occurred due to ongoing disease activity and/or may have affected CSF IL-17A levels), we analyzed the levels of CSF IL-17A in patients who were treated vs. untreated. The results indicated similar levels of CSF IL-17A in treated vs. untreated patients in both RRMS cohorts ( Supplementary Fig. 2 ).
The presence of IL-6 signaling alongside IL-17A was shown to be important on disrupting barrier function in hCMEC/D3 human brain endothelial cell line, by decreasing the expression of genes encoding tight junction, adherens junction and adhesion proteins. IL-17A has also been reported to disrupt the BBB through modification of the localization of TJ proteins and the underlying cytoskeleton (Rahman, Ghosh, 2018) . Therefore, multiple levels of regulation of this process by IL-17A are possible. IL-17 by itself has been reported to have the ability to disrupt the barrier integrity of human brain-derived primary microvascular endothelial cells (Kebir, Kreymborg, 2007) and a murine brain endothelial cell line, bEnd.3, at a higher concentration (Huppert, Closhen, 2010) . However, in our system, the effects of IL-17A alone are not sufficient to result in the disruption of the barrier integrity of the hCMEC/D3 cell line. We believe this difference in response to IL-17A could be attributed to different sensitivity of different cells to IL-17A. Synergistic effect of IL-6
and IL-17 has been shown in previous studies using other cell types, such as astrocytes (Ma et al. , 2010) and structural lung cells (van den Berg et al. , 2005) . This also appears
to be the case in our system, where the stronger effect of combining of IL-6 and IL-17A is required to see physiological effects on the brain endothelial cells monolayer permeability.
Our studies of EAE mice and human CSF showed the importance of IL-17A, but not IL-17F, in EAE development and in RRMS in humans where its elevation in CSF was accompanied by increased BBB permeability. These data support a previous report that IL-17A ablation reduced BBB disruption in EAE (Huppert, Closhen, 2010) . by Wilcoxon rank sum test). Lines: median.
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